Epstein-Barr virus encoded latent membrane protein-1 induces epithelial cell proliferation and sensitizes transgenic mice to chemical carcinogenesis

Cancer Research

Volumn 61, Issue 18, 2001, Pages 6730-6738

  Curran, John A ^a   Laverty, Fiona S ^a   Campbell, Donald ^a   Macdiarmid, Jennifer ^a   Wilson, Joanna B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CYTOKERATIN; LATENT MEMBRANE PROTEIN 1; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; EPIDERMIS; EPITHELIUM CELL; EPSTEIN BARR VIRUS; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MITOSIS; MOUSE; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR PROMOTION; VIRUS CARCINOGENESIS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CARCINOMA; CELL DIFFERENTIATION; CELL DIVISION; COCARCINOGENESIS; CROSSES, GENETIC; EPIDERMIS; EPITHELIAL CELLS; HERPESVIRUS 4, HUMAN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PAPILLOMA; SKIN NEOPLASMS; TONGUE; VIRAL MATRIX PROTEINS;

EID: 0035884394     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Epstein-Barr virus
2. IARC Monographs on the evaluation of carcinogenic risks to humans
3. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region
4. Volatile nitrosamine levels in common foods from Tunisia, south China and Greenland, high-risk areas for nasopharyngeal carcinoma (NPC)
5. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: Report of a case-control study in Hong Kong
6. Diet and nasopharyngeal carcinoma: A case-control study in Guangzhou, China
7. Volatile N-nitrosamines and their precursors in Chinese salted fish - A possible etiological factor for NPC in China
8. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: Evidence for a viral protein expressed in vivo
9. Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells
10. Differential expression of Epstein-Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells
11. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts
12. Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas
13. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma
14. EBV gene expression in an NPC-related tumour
15. Novel transcription from the Epstein-Barr virus terminal EcoRI fragment. DIJhet, in a nasopharyngeal carcinoma
16. Expression of a family of complementary-strand transcripts in Epstein-Barr virus-infected cells
17. Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells
18. Structural analyses of the Epstein-Barr virus BamHI A transcripts
19. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus
20. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus
21. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues
22. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein
23. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
24. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus
25. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts
26. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6
27. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus
28. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation
29. Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells
30. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1
31. Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells
32. Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma
33. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas
34. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule
35. Epstein Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival
36. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor
37. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
38. Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1
39. Localization of the major NF-κB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signalling motifs
40. Characterization of LMP-1’s association with TRAF1, TRAF2, and TRAP3
41. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB
42. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NP-κB activation
43. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
44. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain
45. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus
46. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
47. Activation of the c-Jun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)
48. Constitutive expression of HLA class II antigens on EBV positive malignant cells from nasopharyngeal carcinoma: Possible involvement in T cell infiltration
49. Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells
50. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating NF-κB
51. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor
52. Epstein-Barr virus-encoded LMP1, and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors
53. Genetic events and the role of TGFβ in epithelial tumour progression
54. Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons
55. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis
56. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
57. Cyclin D1 overexpression in mouse epidermis increases cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development
58. Crystal structure of the cys2 activator-binding domain of protein kinase C δ in complex with phorbol ester
59. Mechanistically different acting tumor promoters induce consistent qualitative and quantitative changes in protein expression patterns of murine epidermis
60. Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter
61. Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v-Ha-ras oncogene
62. Targeted overexpression of transforming growth factor-α in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas
63. Transgenic mice provide genetic evidence that transforming growth factor-α promotes skin tumorigenesis via H-ras-dependent and H-ras-independent pathways
64. Ha, v-fos, or human transforming growth factor-α
65. The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted
66. Transgenic mice provide new insights into the role of TGF-α during epidermal development and differentiation
67. Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia
68. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid
69. HA-activated papillomas and carcinomas without p53 mutation: Association of v-fos expression with promotion and tumor autonomy
70. Considerations in generating transgenic mice: DNA, RNA and protein extractions from tissues-rapid and effective blotting
71. Three cDNA sequences of mouse type I keratins. Cellular localization of the mRNAs in normal and hyperproliferative tissues
72. In vivo assay of cellular proliferation
73. Topical chemical carcinogen treatment in mice
74. Detection of EBV latent proteins by Western blotting
75. Transgenic mouse model of X-linked cleft palate
76. Murine CASK is disrupted in a sex-linked cleft palate mouse mutant
77. Studies on the mechanism of skin tumor promotion
78. Metastatic potential of mouse skin carcinomas produced by different protocols of chemical carcinogenesis
79. Differentiation-specific expression of human keratin 1 is mediated by a composite AP-1/steroid hormone element
80. Fos-related antigen (Fra-1), junB, and junD activate human involucrin promoter transcription by binding to proximal and distal AP1 sites to mediate phorhol ester effects on promoter activity
81. Effect of AP1 transcription factors on the regulation of transcription in normal human epidermal keratinocytes
82. Regulation of human evolucrin promoter activity by a protein kinase C, Ras, MEKK1, MEK3, p38/RK, AP1 signal transduction pathway
83. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB
84. Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes
85. TGFα and v-fos cooperation in transgenic mouse epidermis induces aberrant keratinocyte differentiation and stable, autonomous papillomas
86. Transgenic overexpression of transforming growth factor-α bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis
87. Epidermal expression of transforming growth factor-α in transgenic mice: Induction of spontaneous and 12-O-tetradecanoylphorbol-13-acetate-induced papillomas via a mechanism independent of Ha-ras activation or overexpression
88. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
89. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma